Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2014-10-08 AGM Information
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Annual General Meeting Date 1 page 20.6KB
AGM Information Classification · 95% confidence The document is a short announcement dated 9th October 2014 from Phylogica Ltd regarding the date and time of its upcoming Annual General Meeting (AGM) scheduled for 27th November 2014. It does not contain any financial data, detailed reports, or voting results. It simply informs shareholders and the market about the AGM date. The document length is only 553 characters, indicating it is a brief notice rather than a full report or presentation. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during or about the AGM, or announcements related to the AGM itself. Given the brevity and content, AGM-R is the most appropriate classification with high confidence.
2014-10-08 English
Investor Presentation 21 pages 2.9MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation about Phylogica Limited, covering its business overview, technology, partnerships, market focus, and upcoming milestones. It includes forward-looking statements, disclaimers, and contact information. The content is structured as slides with visuals and explanatory text, typical of an investor or corporate presentation. There are no financial statements, audit details, voting results, or regulatory certifications. The document is not a report itself but a presentation aid intended to update investors or stakeholders on the company's business and strategy. Therefore, it fits the category of an Investor Presentation (IP). The document length (over 12,000 characters) supports it being a full presentation rather than a brief announcement or summary.
2014-09-17 English
Grant for Cancer Drug Research 3 pages 26.7KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Phylogica Ltd regarding the receipt of a research grant from the Australian Research Council to develop novel cancer drug candidates. It is a corporate news release about a grant award and research collaboration, with no financial data, no regulatory filing references, no meeting or voting information, no financial results, and no mention of any report publication. The content is informational about a scientific grant and partnership, which fits best under general regulatory announcements or miscellaneous filings that do not fit other categories. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is 7643 characters, which is sufficient for a full announcement rather than a brief note, supporting this classification.
2014-09-01 English
Phylogica Patents Granted 2 pages 71.6KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the granting of patents in the US and Japan related to Phylogica's technology. It discusses intellectual property updates, patent numbers, and the strategic importance of these patents. There is no financial data, no regulatory filing references, no meeting or voting information, no management or board changes, no earnings or financial results, and no mention of any report being attached or published. The content is primarily an announcement of patent grants, which is a regulatory announcement but does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a report itself but an announcement of intellectual property developments. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories.
2014-08-27 English
Appendix 4E and Audited Annual Financial Statements 55 pages 335.3KB
Annual Report Classification · 100% confidence The document is titled 'Appendix 4E Preliminary final report Year ended 30 June 2014' for Phylogica Limited. It includes detailed financial data such as revenues, profit/loss, net tangible assets, directors' report, auditor's independence declaration, financial statements (comprehensive income, financial position, cash flows, changes in equity), notes to financial statements, directors' declaration, independent auditor's report, and corporate governance statement. The document covers the full fiscal year ended 30 June 2014 and contains comprehensive audited financial information. The presence of a full annual financial report and detailed directors' report indicates this is the official yearly report covering company activity and full financial performance. Therefore, this document fits the definition of an Annual Report (10-K equivalent). FY 2014
2014-08-27 English
Research Service Agreement with Genentech 1 page 86
Regulatory Filings Classification · 95% confidence The document is a short announcement about Phylogica entering into a research service agreement with Genentech. It provides background information about the company and the nature of the agreement but does not contain any financial data, regulatory filings, or detailed reports. The length is only 2014 characters, which is quite short and typical for a press release or announcement. There is no indication of financial results, management changes, voting results, or other specific report types. Therefore, this document fits best as a Regulatory Filing (RNS), which is a general category for miscellaneous announcements that do not fit other specific categories.
2014-08-17 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.